Retrospective Study of the Prevalence of Antiphospholipid Antibodies in the Population of Hemodialysis Patients at the CHU Brugmann Hospital
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Maturation delay of the arteriovenous fistula
研究概览
简要总结
In patients with a chronic renal disease at the terminal stage, extrarenal epuration is essential for the control of clinico-biological complications. Two extrarenal epuration techniques are currently available: peritoneal dialysis (using the peritoneal membrane of the patient) and hemodialysis, requiring the use of an external biocompatible membrane known as 'dialysis filter'. This technique requires a vascular access (arteriovenous fistula or dialysis catheter). The thrombosis of vascular accesses represents a major cause of morbidity and mortality in hemodialysis patients. Thrombosis are more frequent when using synthetic prosthetic arteriovenous fistula instead of native arteriovenous fistula.
Antiphospholipid Syndrome (APLS) is a rare autoimmune disease characterized by arterial thrombosis, venous thrombosis and obstetrical complications such as as defined by the Sidney's criteria.
In the general population, the presence of antiphospholipid antibodies is associated with an increased risk of thromboembolic events. In the nephrological population, this prevalence is higher in hemodialysis patients compared to patients on peritoneal dialysis or non-dialyzed patients. Up to 37% of hemodialysis patients are positive for antiphospholipid antibodies and this biology is associated with thrombotic events and vascular access thromboses. However, some studies do not report this association and there is currently no consensus in terms of the therapeutic management of these patients.
Some factors influencing the positivity for antiphospholipid antibodies have been reported: smoking, age, the presence of a non-glomerular nephropathy, hypoalbuminaemia, the use of a central venous catheter for dialysis or the use of a non-biocompatible dialysis membrane.
Taking into account the conflicting data from the literature, it seems important to study the respective role(s) of 3 types of antiphospholipid antibodies in the occurrence of thrombo- embolic events in patients undergoing dialysis within the CHU Brugmann Hospital.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients undergoing dialysis within the CHU Brugmann Hospital
排除标准
- •Mutation of factor V
- •Mutation G20210A of the prothrombin gene
- •Protein C deficiency
- •Protein S deficiency
- •Antithrombin III deficiency
结局指标
主要结局
Maturation delay of the arteriovenous fistula
时间窗: 19 years
Maturation delay of the arteriovenous fistula
Percentage of thrombosis of the filter
时间窗: 19 years
Percentage of thrombosis of the filter
Lifespan of the fistula
时间窗: 19 years
Lifespan of the fistula
Prevalence of antiphospholipid antibodies
时间窗: 19 years
Prevalence of antiphospholipid antibodies
Prevalence of venous thrombosis
时间窗: 19 years
Prevalence of venous thrombosis
Lifespan of the catheter
时间窗: 19 years
Lifespan of the catheter
Prevalence of arterial thrombosis
时间窗: 19 years
Prevalence of arterial thrombosis
次要结局
- Brand of dialysis membrane(19 years)
- Hemoglobin count(Last available result within 19 years)
- Vascular access(19 years)
- Urea change percentage(Last available result within 19 years)
- Antihypertensive treatment(19 years)
- Age at dialysis entry(19 years)
- Anticoagulant treatment(19 years)
- Antiplatelet treatment Antiplatelet treatment(19 years)
- Type of dialysis(19 years)
- Statin treatment(19 years)
- Ethiology of the nephropathy (known/unknown)(19 years)
- Type of per-dialytic anticoagulation(19 years)
- Platelets count(Last available result within 19 years)
- Existence of thrombosis risk factors(19 years)
- Ethiology of the nephropathy (glomerular)(19 years)
- Activated partial thromboplastin time (aPTT)(Last available result within 19 years)
研究者
Agnieszka Pozdzik
Head of clinic
Brugmann University Hospital